Budget impact models and customer facing tools

Healthcare payer budgets are limited and under constant pressure from ever increasing demand and spiralling treatment costs. Payers therefore rely on budget impact modelling to evaluate the financial impact of adding new pharmaceutical products to their formularies, at the national, regional and local levels.

We tailor each model to the specific indication to ensure we capture disease, patient and product-related nuances. Our models are designed to be fully functional, user friendly and interactive, for optimal impact with a specific target payer audience.

Flexible model framework with a user-friendly interface in Excel or R

Support for global models and country-level adaptations

Interactivity to support end-user navigation, transparency of calculations and references, and ease of understanding core economic value messages

If you want a digital solution that you can easily and instantly adapt to the payer environment, our e‑v@luate IMPACT™ platform offers a seamless, user-friendly tool to visualise health economic information and communicate the economic value of your product. As a web-based and tablet-friendly solution with focused content relevant to the specific payer audience, it provides a simple interface that is easily adaptable to each customer scenario, thus directly supporting economic discussions in the field to communicate a tailored economic value story for your product.

View a case study on a previous budget impact models project

Assessing the budget impact of a new treatment for the management of a chronic disease

LEARN MORE

Health Economics & Data Analysis

Click here for details of our wider expertise and our database of published research and conference presentations

LEARN MORE

Assessing the budget impact of a new treatment for the management of a chronic disease

Development of a budget impact model (BIM) to demonstrate the economic value and cost savings of an anti-obesity medication (AOM)

The challenge

Our client required a global health technology assessment (HTA) compliant BIM to demonstrate the value of introducing their product to the obesity treatment landscape. The model needed to be flexible to facilitate country adaptations in order to support HTA submissions globally. Obesity is associated with multiple comorbidities such as diabetes, heart disease and hypertension, which contribute largely to the burden placed on healthcare budgets. It was imperative the model considered such comorbidities to estimate the true value associated with reductions in obesity levels. Finally, it was of particular importance to our client that the model be user friendly and aesthetically pleasing.

The solution

A flexible, HTA compliant, global BIM was developed demonstrating the cost saving potential of an antiobesity medication (AOM) for the treatment of obesity. The global BIM’s flexibility allowed end-users to update the BIM in line with their relevant settings, as the label varied among countries. For example, they could include or exclude different populations, such as patients with diabetes. The model accounted for drug costs, treatment related costs and cost savings stemming from a decrease in the levels of obesity and its comorbidities. Furthermore, it provided transparency on data sources and flexibility, allowing the user to edit any of the inputs to test various assumptions and scenarios.

Key results

The model enabled users to actively compare the following outcomes after the introduction of the AOM against the current standard of care for obesity:

> Number of patients eligible for treatment
> Cost per year in the reference and in the new scenario
> Budget impact broken down by treatment option and cost type
> Key drivers of budget impact, through deterministic sensitivity analysis.

Value to the client

Our client was able to test various scenarios in multiple countries, allowing them to pursue their global market access strategy. The model was developed with a wide scope to ensure maximum utility for a range of stakeholders, including technical users and decision makers.